Breaking News, Promotions & Moves

Medincell Appoints Three New Members to Board of Directors

Sharon Mates, Charles Kunsch, & Pascal Touchon will help shape strategic vision, leadership, and company impact.

By: Rachel Klemovitch

Assistant Editor

Medincell’s General Assembly held on September 11, 2025, appointed three new independent board members: Dr Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon.

Philippe Guy, Chairman of Medincell’s Board, said: “With the election of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon, we welcome a wealth of additional experience in innovation, strategic vision, and influential networks to our Board. Their contributions will be instrumental in shaping Medincell’s future by reinforcing our leadership, expanding our impact, and creating lasting value.”

Dr. Sharon Mates, PhD, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, a CNS-focused biotech that developed the successful drug CAPLYTA, acquired by Johnson & Johnson in April 2025.

Dr. Charles Kunsch, PhD, is a seasoned life sciences executive with over 30 years of experience, including as former Managing Director at AbbVie Ventures, where he led investments in pioneering biotech companies.

Dr. Pascal Touchon, DVM, has over 40 years of international leadership in the biopharmaceutical industry, including key roles at Novartis Oncology and Atara Biotherapeutics and current board positions at Ipsen, CDR-Life, RoslinCT, Catalym, and Xylocor.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters